APS News

May 2004 (Volume 13, Number 5)

"Smart" Drugs Target Cancer Cells

One of the bitter ironies of cancer therapy is that any treatment powerful enough to kill tumor cells also harms healthy ones, causing undesirable side effects.

Researchers at the University of Michigan's Center for Biologic Nanotechnology are developing "smart" drug delivery systems that will hopefully help prevent that problem by knocking out cancer cells with lethal doses while leaving normal cells unharmed.

The U-M group is using lab-made molecules called dendrimers—also known as nanoparticles—as the backbones of their delivery system, according to U-M graduate student Almut Mecke, who reported on the group's progress at the APS March Meeting in Montréal.

Dendrimers are tiny spheres that have been carefully engineered to have several loose ends, to which other molecules can be attached, such as a targeting agent that can recognize a cancer cell and distinguish it from a healthy cell, or a drug that kills cancer cells. This turns the dendrimer into a cancer-fighting Trojan horse. "If you have both of these functions on the same molecule, then you have a smart drug that knows which cells to attack," said Mecke.

In order for this approach to be successful, the bare dendrimer should not be toxic and should not be able to break into healthy cells, only cancerous ones. So Mecke investigated the interaction of dendrimers with cell membranes. She found that certain kinds of dendrimers are able to disrupt membranes by literally punching holes in them—not a desirable attribute, since they do not distinguish between cancerous and healthy cells. The underlying mechanism seems to arise from the membrane wrapping itself around the dendrimer, leaving a hole.

This happens because both the dendrimers and cell membranes are charged, causing the two to bind. Mecke's group modified the dendrimers chemically so that they became uncharged, and no longer punched holes in membranes. Of course, uncharged dendrimers don't attack any cells at all, so cancer-detecting targeting agents must be attached.

Mecke's group is working with a type of dendrimer called polyamidoamine, which is modified to identify cancer cells containing specific markers on their membrane surface. This causes the cancer cell to ingest the dendrimer. Once inside the cell, it releases the attached anti-cancer drug.

The data Mecke gleaned through atomic force microscopy is supported by recent research on live human cancer cells in-vitro, as well as animal tests conducted by team members. Initial results on mice have shown a greater efficiency and reduced side effects when cancer is treated nano-therapeutically.

The researchers hope next to add more functions to their dendrimer-drug devices, such as biosensors that can report on cancer cell death, indicating how successful a particular treatment has been.

APS encourages the redistribution of the materials included in this newspaper provided that attribution to the source is noted and the materials are not truncated or changed.

Editor: Alan Chodos
Associate Editor: Jennifer Ouellette

May 2004 (Volume 13, Number 5)

APS News Home

Issue Table of Contents

APS News Archives

Contact APS News Editor

Articles in this Issue
Global Representatives Gather To Plan World Year of Physics
AFM Study shows old Cells Lose Their Elasticity
APS Hydrogen Report Attracts the Media
Women Physicists Learn Survival Skills in Montréal
"Smart" Drugs Target Cancer Cells
Cold Gases, Hot Topic
New Nanodevices Target a Host of Potential Applications
Plasma Physics and Laser Science Offer Distinguished Lecturer Programs
Forum on Education Launches Two Initiatives
Brain Synchronization Can Give You A Headache
Nanofoam Exhibits Surprising Magnetic Properties
The Back Page
Members in the Media
This Month in Physics History
Zero Gravity: The Lighter Side of Science